Cardiac amyloidosis: Diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)

Tanvir Rahman, Reihaneh C. Moghadam, Vikram V. Agarwal, Craig K. Reiss

Research output: Contribution to journalArticlepeer-review

Abstract

ATTR-CA is an under-reported cause of congestive heart failure (CHF) and cardiac arrhythmias. Heightened clinical suspicion along with a multimodal investigative approach is often required in diagnosing this potentially fatal condition. Tafamidis and inotersen have shown promising results in terms of progression-free survival by ameliorating CHF symptoms and peripheral neuropathies in clinical trials. In this case series of five patients, we present three wild-type cardiac amyloidosis (ATTRwt-CA), one familial cardiac amyloidosis (ATTRm-CA) and one primary cardiac (AL-CA). The diagnostic modality was different for each patient. ATTRwt-CA, ATTRm-CA and AL-CA patients received tafamidis, inotersen and chemotherapy with bone marrow stem-cell transplantation, respectively.

Original languageEnglish
Pages (from-to)283-287
Number of pages5
JournalOxford Medical Case Reports
Volume2021
Issue number8
DOIs
StatePublished - Aug 1 2021

Fingerprint

Dive into the research topics of 'Cardiac amyloidosis: Diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)'. Together they form a unique fingerprint.

Cite this